<?xml version="1.0" encoding="utf-8"?>
<rdf:RDF
                     xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
                     xmlns="http://purl.org/rss/1.0/"
                     xmlns:dc="http://purl.org/dc/elements/1.1/"
                    >
<channel rdf:about="http://www.expertoentrombosis.com"><title>Noticias para Experto en Trombosis</title>
<link>http://www.expertoentrombosis.com</link>
<description><![CDATA[Latest Updates and News on Xarelto and ThrombosisAdviser.com]]></description>
<items>
<rdf:Seq>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Post-MI+Warfarin+Underused+in+Afib#news948"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Warfarin+Use+Related+to+Several+Factors#news947"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+No+Link+Between+Insulin+Resistance+and+Afib#news946"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Stroke+History+Tied+to+Renal+Function+in+Afib#news945"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=BMS%2C+Pfizer+halt+Apixaban+Phase+3+APPRAISE-2+trial#news944"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Guidelines+Not+a+Factor+in+Warfarin+Choices#news943"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Hidden+Arrhythmias+May+Increase+Stroke+Risk#news942"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Major+Study+Shows+Ability+of+New+Agent+to+Prevent+Strokes+in+Patients+with+Atrial+Fibrillation#news941"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Omega-3+Supplements+Won%27t+Fight+Irregular+Heartbeat#news940"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=GRAVITAS%3A+High-dose+clopidogrel+did+not+improve+post-PCI+outcomes#news939"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Electrical+Cardioversion+Beneficial+for+Older+Adults+With+Atrial+Fibrillation%3A+Presented+at+AHA#news938"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=For+Coronary+Patients%2C+H2RA+Plus+Clopidogrel+Spikes+Risk#news937"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Effect+of+Clopidogrel+in+Patients+With+ACS+Appears+Consistent+Regardless+of+CYP2C19+Genotype%3A+Presented+at+CCC#news936"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Clopidogrel+and+the+Reduced-Function+CYP2C19+Genetic+Variant#news935"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Risk+of+Recurrence+After+a+First+Episode+of+Symptomatic+Venous+Thromboembolism+Provoked+by+a+Transient+Risk+Factor#news934"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Home+Monitoring+of+Blood-Thinner+Use+Appears+Effective#news933"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Patient-Level+Meta-analysis%3A+Effect+of+Measurement+Timing%2C+Threshold%2C+and+Patient+Age+on+Ability+of+d-Dimer+Testing+to+Assess+Recurrence+Risk+After+Unprovoked+Venous+Thromboembolism#news932"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Increasing+Catheter+Size+Tied+to+Greater+Thrombosis+Risk#news931"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Pharmacists%27+involvement+in+warfarin+therapy+reduced+total+bleeding+by+half#news930"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=In+the+absence+of+a+central+venous+catheter%2C+risk+of+venous+thromboembolism+is+low+in+critically+injured+children%2C+adolescents%2C+and+young+adults%3A+Evidence+from+the+National+Trauma+Data+Bank#news929"/>
<rdf:li resource="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Elevated+C-Reactive+Protein+a+Risk+Factor+for+Early+Stroke-Related+Deep+Venous+Thrombosis%3A+Presented+at+EFNS#news928"/>
</rdf:Seq>
</items>
</channel>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Post-MI+Warfarin+Underused+in+Afib#news948">
<title>AHA&#58; Post&#45;MI Warfarin Underused in Afib</title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Post-MI+Warfarin+Underused+in+Afib#news948</link>
<dc:date>2010-11-22</dc:date>
<description><![CDATA[Less than half of heart attack patients with recent atrial fibrillation get warfarin at discharge, according to a registry study. ]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Warfarin+Use+Related+to+Several+Factors#news947">
<title>AHA&#58; Warfarin Use Related to Several Factors  </title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Warfarin+Use+Related+to+Several+Factors#news947</link>
<dc:date>2010-11-22</dc:date>
<description><![CDATA[Many factors aside from the CHADS2 stroke risk score appear to contribute to the decision to give warfarin to patients newly diagnosed with atrial fibrillation, researchers found. ]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+No+Link+Between+Insulin+Resistance+and+Afib#news946">
<title>AHA&#58; No Link Between Insulin Resistance and Afib </title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+No+Link+Between+Insulin+Resistance+and+Afib#news946</link>
<dc:date>2010-11-22</dc:date>
<description><![CDATA[Insulin resistance is not associated with the development of atrial fibrillation, according to an analysis of the Framingham Heart Study. ]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Stroke+History+Tied+to+Renal+Function+in+Afib#news945">
<title>AHA&#58; Stroke History Tied to Renal Function in Afib</title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Stroke+History+Tied+to+Renal+Function+in+Afib#news945</link>
<dc:date>2010-11-22</dc:date>
<description><![CDATA[In patients who have undergone cardioversion for atrial fibrillation, impaired renal function appears to be associated with a history of stroke, researchers found. ]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=BMS%2C+Pfizer+halt+Apixaban+Phase+3+APPRAISE-2+trial#news944">
<title>BMS&#44; Pfizer halt Apixaban Phase 3 APPRAISE&#45;2 trial</title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=BMS%2C+Pfizer+halt+Apixaban+Phase+3+APPRAISE-2+trial#news944</link>
<dc:date>2010-11-19</dc:date>
<description><![CDATA[There was clear evidence of a clinically important increase in bleeding among patients randomised to Apixaban, which was not offset by clinically meaningful reductions in ischemic events.]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Guidelines+Not+a+Factor+in+Warfarin+Choices#news943">
<title>AHA&#58; Guidelines Not a Factor in Warfarin Choices</title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Guidelines+Not+a+Factor+in+Warfarin+Choices#news943</link>
<dc:date>2010-11-19</dc:date>
<description><![CDATA[Clinicians do not seem to be relying on the recommended stroke risk score to prescribe warfarin for patients with atrial fibrillation, researchers found.]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Hidden+Arrhythmias+May+Increase+Stroke+Risk#news942">
<title>AHA&#58; Hidden Arrhythmias May Increase Stroke Risk</title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=AHA%3A+Hidden+Arrhythmias+May+Increase+Stroke+Risk#news942</link>
<dc:date>2010-11-19</dc:date>
<description><![CDATA[Asymptomatic atrial arrhythmias detected by a pacemaker or implantable cardioverter-defibrillator are associated with an increased stroke risk, a prospective cohort study showed.]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Major+Study+Shows+Ability+of+New+Agent+to+Prevent+Strokes+in+Patients+with+Atrial+Fibrillation#news941">
<title>Major Study Shows Ability of New Agent to Prevent Strokes in Patients with Atrial Fibrillation</title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Major+Study+Shows+Ability+of+New+Agent+to+Prevent+Strokes+in+Patients+with+Atrial+Fibrillation#news941</link>
<dc:date>2010-11-19</dc:date>
<description><![CDATA[In the primary result from the largest double-blind study ever completed to assess a drug’s effect in the prevention of stroke in patients with atrial fibrillation, a common heart rhythm abnormality, rivaroxaban, an anti-clotting drug, was shown to be superior to warfarin, the current standard for treatment of atrial fibrillation, while patients in the study were taking study drug.]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Omega-3+Supplements+Won%27t+Fight+Irregular+Heartbeat#news940">
<title>Omega&#45;3 Supplements Won&#39;t Fight Irregular Heartbeat</title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Omega-3+Supplements+Won%27t+Fight+Irregular+Heartbeat#news940</link>
<dc:date>2010-11-17</dc:date>
<description><![CDATA[Omega-3 fatty acid supplements don't cut back on recurrences of atrial fibrillation, a type of irregular heartbeat that can cause stroke, new research suggests.]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=GRAVITAS%3A+High-dose+clopidogrel+did+not+improve+post-PCI+outcomes#news939">
<title>GRAVITAS&#58; High&#45;dose clopidogrel did not improve post&#45;PCI outcomes</title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=GRAVITAS%3A+High-dose+clopidogrel+did+not+improve+post-PCI+outcomes#news939</link>
<dc:date>2010-11-17</dc:date>
<description><![CDATA[High-dose clopidogrel was not superior to the standard dose in reducing CV death, non-fatal MI or stent thrombosis following PCI among patients with high residual platelet reactivity.]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Electrical+Cardioversion+Beneficial+for+Older+Adults+With+Atrial+Fibrillation%3A+Presented+at+AHA#news938">
<title>Electrical Cardioversion Beneficial for Older Adults With Atrial Fibrillation&#58; Presented at AHA</title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Electrical+Cardioversion+Beneficial+for+Older+Adults+With+Atrial+Fibrillation%3A+Presented+at+AHA#news938</link>
<dc:date>2010-11-16</dc:date>
<description><![CDATA[Electrical cardioversion significantly reduces the risk of death in older patients with atrial fibrillation, according to a study presented here today at the American Heart Association (AHA) Scientific Sessions 2010.]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=For+Coronary+Patients%2C+H2RA+Plus+Clopidogrel+Spikes+Risk#news937">
<title>For Coronary Patients&#44; H2RA Plus Clopidogrel Spikes Risk</title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=For+Coronary+Patients%2C+H2RA+Plus+Clopidogrel+Spikes+Risk#news937</link>
<dc:date>2010-11-16</dc:date>
<description><![CDATA[The concomitant use of a histamine2-receptor antagonist and clopidogrel for patients with prior acute coronary syndrome more than doubles the risk of rehospitalization or death compared to treatment with clopidogrel only, according to research published in the October issue of Gastroenterology.]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Effect+of+Clopidogrel+in+Patients+With+ACS+Appears+Consistent+Regardless+of+CYP2C19+Genotype%3A+Presented+at+CCC#news936">
<title>Effect of Clopidogrel in Patients With ACS Appears Consistent Regardless of CYP2C19 Genotype&#58; Presented at CCC</title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Effect+of+Clopidogrel+in+Patients+With+ACS+Appears+Consistent+Regardless+of+CYP2C19+Genotype%3A+Presented+at+CCC#news936</link>
<dc:date>2010-11-16</dc:date>
<description><![CDATA[The effect of clopidogrel compared with placebo in patients with acute coronary syndromes (ACS) or atrial fibrillation (AF) appears to be consistent irrespective of CYP2C19 genotype, according to research presented here October 28 at the 2010 Canadian Cardiovascular Congress (CCC).]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Clopidogrel+and+the+Reduced-Function+CYP2C19+Genetic+Variant#news935">
<title>Clopidogrel and the Reduced&#45;Function CYP2C19 Genetic Variant</title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Clopidogrel+and+the+Reduced-Function+CYP2C19+Genetic+Variant#news935</link>
<dc:date>2010-11-16</dc:date>
<description><![CDATA[Effective platelet inhibition has become a cornerstone in the management of patients with acute coronary syndrome (ACS). Yet studies have demonstrated that the therapeutic response of clopidogrel is variable among patients, and low or incomplete platelet inhibition has been associated with increased risk for major adverse cardiovascular events.]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Risk+of+Recurrence+After+a+First+Episode+of+Symptomatic+Venous+Thromboembolism+Provoked+by+a+Transient+Risk+Factor#news934">
<title>Risk of Recurrence After a First Episode of Symptomatic Venous Thromboembolism Provoked by a Transient Risk Factor</title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Risk+of+Recurrence+After+a+First+Episode+of+Symptomatic+Venous+Thromboembolism+Provoked+by+a+Transient+Risk+Factor#news934</link>
<dc:date>2010-10-27</dc:date>
<description><![CDATA[The risk of recurrence is low if VTE is provoked by surgery, intermediate if provoked by a nonsurgical risk factor, and high if unprovoked. These risks affect whether patients with VTE should undergo short-term vs indefinite treatment.]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Home+Monitoring+of+Blood-Thinner+Use+Appears+Effective#news933">
<title>Home Monitoring of Blood&#45;Thinner Use Appears Effective </title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Home+Monitoring+of+Blood-Thinner+Use+Appears+Effective#news933</link>
<dc:date>2010-10-26</dc:date>
<description><![CDATA[The study, which is published in the Oct. 21 issue of the New England Journal of Medicine, found that weekly home tests were similarly effective to monthly clinic testing for patients taking warfarin therapy. ]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Patient-Level+Meta-analysis%3A+Effect+of+Measurement+Timing%2C+Threshold%2C+and+Patient+Age+on+Ability+of+d-Dimer+Testing+to+Assess+Recurrence+Risk+After+Unprovoked+Venous+Thromboembolism#news932">
<title>Patient&#45;Level Meta&#45;analysis&#58; Effect of Measurement Timing&#44; Threshold&#44; and Patient Age on Ability of d&#45;Dimer Testing to Assess Recurrence Risk After Unprovoked Venous Thromboembolism</title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Patient-Level+Meta-analysis%3A+Effect+of+Measurement+Timing%2C+Threshold%2C+and+Patient+Age+on+Ability+of+d-Dimer+Testing+to+Assess+Recurrence+Risk+After+Unprovoked+Venous+Thromboembolism#news932</link>
<dc:date>2010-10-20</dc:date>
<description><![CDATA[In patients with a first unprovoked venous thromboembolism (VTE), an elevated d-dimer level after anticoagulation is stopped is a risk factor for recurrent VTE.]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Increasing+Catheter+Size+Tied+to+Greater+Thrombosis+Risk#news931">
<title>Increasing Catheter Size Tied to Greater Thrombosis Risk </title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Increasing+Catheter+Size+Tied+to+Greater+Thrombosis+Risk#news931</link>
<dc:date>2010-10-07</dc:date>
<description><![CDATA[Previous deep vein thrombosis and increasing catheter size are related to an increased risk for peripherally inserted central catheter-associated deep vein thrombosis, according to a study in the October issue of Chest. ]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Pharmacists%27+involvement+in+warfarin+therapy+reduced+total+bleeding+by+half#news930">
<title>Pharmacists&#39; involvement in warfarin therapy reduced total bleeding by half</title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Pharmacists%27+involvement+in+warfarin+therapy+reduced+total+bleeding+by+half#news930</link>
<dc:date>2010-10-07</dc:date>
<description><![CDATA[Results from a meta-analysis conducted by researchers in Thailand, Australia and the United States showed that pharmacist-participated warfarin management reduced total bleeding by nearly 50% compared with usual care. ]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=In+the+absence+of+a+central+venous+catheter%2C+risk+of+venous+thromboembolism+is+low+in+critically+injured+children%2C+adolescents%2C+and+young+adults%3A+Evidence+from+the+National+Trauma+Data+Bank#news929">
<title>In the absence of a central venous catheter&#44; risk of venous thromboembolism is low in critically injured children&#44; adolescents&#44; and young adults&#58; Evidence from the National Trauma Data Bank </title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=In+the+absence+of+a+central+venous+catheter%2C+risk+of+venous+thromboembolism+is+low+in+critically+injured+children%2C+adolescents%2C+and+young+adults%3A+Evidence+from+the+National+Trauma+Data+Bank#news929</link>
<dc:date>2010-10-07</dc:date>
<description><![CDATA[Venous thromboembolism is rare in young critical care trauma patients, even older adolescents. However, venous thromboembolism prophylaxis may need to be considered only in critically injured adolescents and young adults with a continuing need for central venous access. ]]></description>
</item>
<item rdf:about="http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Elevated+C-Reactive+Protein+a+Risk+Factor+for+Early+Stroke-Related+Deep+Venous+Thrombosis%3A+Presented+at+EFNS#news928">
<title>Elevated C&#45;Reactive Protein a Risk Factor for Early Stroke&#45;Related Deep Venous Thrombosis&#58; Presented at EFNS</title>
<link>http://www.expertoentrombosis.com/scripts/pages/es/resources/newsticker/index.php?WT.cusRSSfeedLink=Elevated+C-Reactive+Protein+a+Risk+Factor+for+Early+Stroke-Related+Deep+Venous+Thrombosis%3A+Presented+at+EFNS#news928</link>
<dc:date>2010-09-30</dc:date>
<description><![CDATA[Patients who have elevated serum C-reactive protein (CRP) at stroke onset have a higher risk of developing deep venous thrombosis (DVT), and could benefit from DVT prophylaxis, according to a study reported at the 14th Congress of the European Federation of Neurological Societies (EFNS).]]></description>
</item>
</rdf:RDF>
